Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.8K
Introduction to Hemostasis01:05

Introduction to Hemostasis

14.0K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.0K
Coagulation01:09

Coagulation

8.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implantation of cancer cells from transoral endoscopic thyroidectomy: a case report.

Gland surgery·2026
Same author

Bariatric Surgery Outcomes in an Italian Single-Center Study: Does Chronotype Matter?

Obesity surgery·2026
Same author

Impact of the Eras Protocols on Costs and Benefits in Two Italian Second-Level Healthcare Centers According to the National Waiting List Management Plan (PNGLA).

Journal of clinical medicine·2026
Same author

Hiatal Hernia Recurrence After Laparoscopic Repair: Is Always a True Recurrence?

Annali italiani di chirurgia·2025
Same author

Letter in response to "Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: a Delphi Consensus".

Cytotherapy·2025
Same author

Gender Differences in Weight Loss Extent Following Bariatric Surgery.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Apr 28, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K

Hemostatic agents for bleeding: recombinant-activated factor VII and beyond.

Massimo Franchini1, Silvia Crestani1, Francesco Frattini1

  • 1Department of Hematology and Transfusion Medicine, Azienda Ospedaliera Carlo Poma, Mantova, Italy.

Seminars in Thrombosis and Hemostasis
|June 18, 2014
PubMed
Summary

Rapid hemostasis is crucial for critical bleeding. This review covers recombinant-activated factor VII and prothrombin complex concentrates for managing bleeding, including reversal of anticoagulants like vitamin K antagonists and direct oral anticoagulants.

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

11.7K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

165

Related Experiment Videos

Last Updated: Apr 28, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

11.7K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

165

Area of Science:

  • Hematology
  • Critical Care Medicine
  • Pharmacology

Background:

  • Critical bleeding is a life-threatening emergency requiring rapid restoration of hemostasis.
  • Various hemostatic agents are available, but their optimal use in specific scenarios requires clear guidance.
  • Recombinant-activated factor VII (rFVIIa) and prothrombin complex concentrates (PCCs) are key therapeutic options.

Purpose of the Study:

  • To review the current status of rFVIIa and PCCs in managing critical bleeding.
  • To explore the safety and effectiveness of these agents in reversing vitamin K antagonist (VKA) effects.
  • To analyze the role of rFVIIa and PCCs in managing bleeding associated with direct oral anticoagulants (DOACs).

Main Methods:

  • Narrative review of existing literature.
  • Analysis of clinical data on rFVIIa and PCCs.
  • Focused review on VKA and DOAC reversal.

Main Results:

  • rFVIIa and PCCs are established options for critical bleeding management.
  • Evidence supports the use of these agents for VKA reversal.
  • Specific considerations exist for DOAC-associated bleeding, with ongoing research.

Conclusions:

  • rFVIIa and PCCs play significant roles in managing critical bleeding and reversing anticoagulation.
  • Careful patient selection and consideration of bleeding context are essential for optimal outcomes.
  • Further research is needed to fully elucidate the role of these agents in DOAC-related hemorrhage.